A lipid particle comprising: (i) a nucleic acid, (ii) 35-65 mol% of a cationic lipid, (iii) 3-12 mol% distearoylphosphatidylcholine (DSPC), (iv) 15-45 mol% cholesterol, and (v) 0.5-10 mol% of a PEG-modified lipid, wherein the mol% is based on 100% total moles of lipids in the lipid particle; and the cationic lipid comprises a head group, two hydrophobic tails, and a central moiety to which the head group and the two hydrophobic tails are directly bonded, wherein (a) the central moiety is a central carbon or nitrogen atom; (b) each hydrophobic tail independently has the formula -(hydrophobic chain)-(ester group)-(hydrophobic chain), wherein the ester group is -OC(O)- or -C(O)O-; and (c) for at least one hydrophobic tail, (I) the terminal hydrophobic chain in the hydrophobic tail is a branched alkyl, where the branching occurs at the α-position relative to the ester group; (II) the hydrophobic tail has the formula -R12-M1-R13, wherein R12 is a C4-C14 alkylene or C4-C14 alkenylene, M1 is the ester group, and R13 is a branched C10-C20 alkyl; (III) the total carbon atom content of the tail -R12-M1-R13 is 21 to 26; and (IV) the ester group is separated from a terminus of the hydrophobic tail by from 6 to 12 carbon atoms.

979 특허의 청구항 1

A method for producing a stabilized mRNA comprising synthesizing a stabilized mRNA molecule encoding a polypeptide, wherein the stabilized mRNA molecule encoding the polypeptide comprises a coding sequence that has an increased Guanine/Cytosine (G/C) content relative to the original coding sequence encoding the polypeptide, said relative G/C content being increased by at least 7 percentage points compared to the original coding sequence encoding the polypeptide, to thereby produce a stabilized mRNA molecule, wherein said increase in relative G/C content results in the elimination of at least one destabilizing sequence element (DSE), wherein the stabilized mRNA molecule exhibits enhanced expression of the polypeptide compared to mRNA having the original coding sequence encoding the polypeptide.

312 특허의 청구항 1

A method for treating or preventing an infectious disease, the method comprising administering an RNA molecule comprising: a) at least one open reading frame (ORF) encoding an antigen from a pathogen associated with the infectious disease; and b) a 3'-untranslated region (3'-UTR) comprising at least two poly(A) sequences, wherein at least one of the poly(A) sequences comprises at least 70 adenine nucleotides, wherein the at least two poly(A) sequence elements are separated by a nucleic acid sequence comprising from 10 to 90 nucleotides, wherein the RNA molecule is administered intramuscularly.

278 특허의 청구항 1

A composition comprising a mRNA comprising: (a) at least one coding sequence encoding a SARS-CoV-2 spike protein (S) at least 95% identical to SEQ ID NO: 10 that is a pre-fusion stabilized spike protein (S_stab) comprising a pre-fusion stabilizing K986P and V987P mutation; (b) at least one heterologous untranslated region (UTR); and (c) at least one pharmaceutically acceptable carrier, wherein the mRNA is complexed or associated with lipid nanoparticles (LNP) and wherein the LNP comprises: (i) at least one cationic lipid according to formula III-3:  

 (ii) at least one neutral lipid, comprising 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC); (iii) at least one steroid, comprising cholesterol; and (iv) at least one PEG-lipid according to formula IVa:  

wherein n has a mean value ranging from 30 to 60, wherein (i) to (iv) are in a molar ratio of about 20-60% cationic lipid, 5-25% neutral lipid, 25-55% sterol, and 0.5-15% PEG-lipid.

493 특허의 청구항 1